Pharmaceutical filing citing Clinical and Translational Science paper — Larimar Therapeutics, 2026-05-14
Larimar TherapeuticsLarimar TherapeuticsNASDAQ LRMR
Filings SEC · Quote Yahoo cited a paper published in Clinical and Translational Science in its regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website as a basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure cited the paper in this way within the press release.
When a U.S.-listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers of the document filed by Larimar Therapeutics on 2026-05-14 were 2.02 Earnings Release · 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in Clinical and Translational Science in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
In April, Larimar published a paper entitled Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling in the peer-reviewed journal Clinical and Translational Science.
What readers should first look at is where the company placed the paper in the press release. Next, they should determine whether the paper supports the company's entire claim or only part of it. To answer the latter question, one must read the full paper. This article, which only read the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this.
The paper's title is Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling, and it was published in Clinical and Translational Science on 2026-04-25. The authors are affiliated with Balance Therapeutics (United States). The summary at the beginning of the paper is called Abstract. This article only read up to that point. The paragraph was written by a person after filtering a draft generated by a machine reading the abstract through numerical comparison, and thus differs in quality from a full-text review.
This study is a clinical trial involving patients with Friedrich's ataxia. It investigated how human prataxin concentrations derived from normal laboratories correlate with various tissues and peripheral matrices. Significant correlations were observed between target tissues such as the brain, heart, and skeletal muscle, and peripheral matrices such as skin and oral epithelial cells. Similar correlations were observed in both animal experiments and patients, supporting the reliability of the research results. However, this study does not guarantee long-term effects in humans.
The abstract does not answer; it remains in the main text and the appendix. This text, which does not go there, leaves the blank as it is. Readers compare the two citations above to determine which sentence in the abstract corresponds to the excerpt cited by the company.
A month later, the stock price was within the middle half of the sample.
The return excluding the portion attributable to market-wide movements is called excess return. The date is recorded in trading days, counting only the days the stock market is open. In terms of the calendar, 20 trading days are approximately one month. The excess return on the day of the regulatory filing and for the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +0.8% | The extent to which it had already moved before the filing |
| regulatory filing day | −5.7% | filing day or first trading day thereafter |
| +1~+5 trading day cumulative | −13.1% | one week |
| +1~+20 trading day cumulative | −11.0% | one month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of −11.0% in this case is within the bottom 44% of the 142 cases in the sample, and it is within the lower half.
| sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −11.0% |
Half of the sample falls between the two middle marks in the table. Check in the table whether this case falls inside or outside of that range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules to apply to future cases.
After the filing, the company submitted these documents.
After the filing date, this company submitted three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the number. The specific event is read in the original text of each link.
- 2026-05-19 8-K Item 5.07 — Results of the Shareholders' Meeting
- 2026-06-29 8-K Item 8.01, 9.01 — Other Events · Financial Statements · Exhibits
- 2026-08-04 8-K Items 2.02,8.01,9.01 — Earnings announcement · Other events · Financial statements·attached documents
What this article does not answer
This article, which only reads abstracts, cannot answer how the paper re-examined what method, where, and to what extent. How many times the paper cited by the company was cited afterward can be rechecked through the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Term Explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The type is indicated by item numbers such as performance, contracts, and executive changes. All the events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company itself by removing the portion that reflects the overall market rise and fall.
- Trading day
- A date counting only the days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary appearing at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the methods.